The FDA has approved a new combination regimen for certain patients with esophageal cell squamous cell carcinoma.  The U.S. Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy for the treatment of patients with untreated PD-L1-positive esophageal squamous cell carcinoma (ESCC) that is unresectable or metastatic.  Tislelizumab-jsgr is an immune checkpoint … Continue reading Tislelizumab-jsgr Plus Chemotherapy Approved as First-line Option for Esophageal Cancer